---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-106676"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2024-10-07T23:59:59+00:00"
generated_at: "2026-05-30T19:17:38.276179+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Black Diamond restructures to focus on BDTX-1535; CFO and CPO depart; cash runway extended to Q2 2026

## Summary
- CFO Fang Ni and CPO Elizabeth Montgomery depart; Erika Jones appointed Principal Financial Officer.
- Restructuring: reduction in force, deprioritize BDTX-4933 to seek partners, outsource CMC activities.
- Cash runway extended into Q2 2026 due to restructuring cost savings.
- BDTX-1535 Phase 2 data in frontline and recurrent EGFRm NSCLC expected Q1 2025 with potential registration path.

## SEC filing metadata
- accession: 0001104659-24-106676
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2024-10-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000110465924106676/0001104659-24-106676-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000110465924106676/tm2425668d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-106676
- JSON: https://secwatch.observer/filing/0001104659-24-106676.json
- Plain text: https://secwatch.observer/filing/0001104659-24-106676.txt

## Key facts
- Executive change
  Erika Jones was appointed as principal financial officer at Black Diamond Therapeutics, Inc..
  - Action: appointed
  - Role: principal financial officer
  source text: Erika Jones, the Company’s Senior Vice President, Finance and Corporate Controller, and principal accounting officer, was appointed as principal financial officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000110465924106676/0001104659-24-106676-index.htm
- Executive change
  Fang Ni was terminated as Chief Business Officer, Chief Financial Officer and principal financial officer at Black Diamond Therapeutics, Inc..
  - Action: terminated
  - Role: Chief Business Officer, Chief Financial Officer and principal financial officer
  source text: On October 7, 2024, Black Diamond Therapeutics, Inc. (the “Company”) terminated Fang Ni, Pharm. D. without Cause (as such term is defined in his employment agreement with the Company, which was filed as Exhibit 10.12 to the Company’s Annual Report on Form 10-K filed on March 9, 2023 (the “Employment Agreement”)) as Chief Business Officer, Chief Financial Officer and principal financial officer of the Company, in each case, effective as of October 7, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000110465924106676/0001104659-24-106676-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.